Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 17/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24175927 | 0.81 | ESR1 (0.39) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL24663909 | 0.81 | ESR1 (0.39) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL24535006 | 0.81 | ESR1 (0.46) | ESR1ESR2TNFRIPK1 | |
| SCHEMBL26059134 | 0.79 | ESR1 (0.39) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL24176030 | 0.79 | GABRA1 (0.40) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL31609498 | 0.79 | ESR1 (0.39) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL24857743 | 0.79 | ESR1 (0.41) | CYP3A4ESR1ESR2TNFRIPK1 | |
| SCHEMBL26667523 | 0.79 | CYP3A4 (0.42) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL24176055 | 0.79 | ESR1 (0.41) | CYP3A4ESR1ESR2TNFRIPK1 | |
| SCHEMBL24652318 | 0.79 | ESR1 (0.37) | CYP3A4CHRM1ALOX15MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023220421-A1 | INHIBITORS OF KRAS(G12D) | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023215802-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215801-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023205719-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023061294-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 再鼎医药(上海)有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023018809-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018810-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022266015-A1 | FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS | KUMQUAT BIOSCIENCES INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022262686-A1 | KRAS G12D INHIBITORS | JINGRUI BIOPHARMA CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022214102-A1 | HETEROCYCLIC COMPOUND ACTING AS KRAS G12D INHIBITOR | 杭州英创医药科技有限公司 | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CYP3A4 3742/4885CHRM1 4880/4885ALOX15 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.